Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
IPO Year:
Exchange: NASDAQ
Website: dyadic.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/18/2022 | Buy → Neutral | Dawson James | |
| 12/17/2021 | $7.00 | Buy | HC Wainwright & Co. |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Dawson James downgraded Dyadic International from Buy to Neutral
HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
10-Q - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
424B5 - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)
Fastest customizable press release news feed in the world
Completed Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of Corporate Website to Prioritize Commercial Execution and Long-term Value CreationCompleted $5.3 million Equity Offering to Strengthen Liquidity and Help Fund Pipeline and Commercial GrowthAchieved Key Development and Commercial Milestones in Life Sciences and Nutrition MarketsAdvanced Multiple Recombinant Protein Programs Toward CommercializationCash, Cash Equivalents, Restricted Cash and Cash Equivalent, and Investment Grade Securities of $7.3 million as of June 30, 2025; Additional $5.3 million of N
JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share. The Company expects the gross proceeds from this offering to be approximately $5.75 million, before deducting the underwriting discount and ot
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock. Closing of the offering is expected to occur on August 1, 2025, subject to customary closing conditions. Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for th
JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Craig-Hallum Capital Gr
Reflects the Company's strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company's transition from a research-driven organization to a commercially foc
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutri
Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, D.C.April 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40
Live Leadership Updates
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and
JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo
Live finance-specific insights
JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025. Conference Call Information Date: Wednesday, August 13, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-
Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the year ended 2024 and host a corporate update conference call on Wednesday, March 26, 2025. Conference Call Information Date: Wednesday, March 26, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-85
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments.Received $1 million milestone payment for animal-free recombinant albumin products.Received $425,000 success fees for achieving production targets in a dairy enzyme collaboration.Expanded recombinant life science protein portfolio within six additional products in development for molecular biology and cell culture media applications. Human Health Co-developed a highly productive C1-produced ferritin nanoparticle Mpox (mo
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the third quarter 2024 and host a corporate update conference call on Tuesday, November 12, 2024. Conference Call Information: Date: Tuesday, November 12, 2024Time: 5:00 p.m. Eastern TimeDial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560Conference
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbuminOngoing development of a robust pipeline of non-pharmaceutical recombinant product candidates such as alpha-lactalbumin, transferrin, DNASE-1, and several potential biofuels and other enzymes utilizing the Dapibus™ platform technology Animal Health Provided samples of the C1-produced recombinant ferritin nanoparticle H5 Clade 2.3.3.4.b A/Astrakhan avian influenza ‘Bird Flu' antigen to multi
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the second quarter 2024 and host a corporate update conference call on Tuesday, August 13, 2024. Conference Call Information: Date: Tuesday, August 13, 2024 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560 Confere
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infectionEntered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companiesSuccessfully expressed a H1N1 influenza antigen in our collaboration with the Vaccine and Immunotherapy Center ("VIC") at Massachusetts General HospitalAnnounced strategic partnership to develop affordable rabies prophylactics and vaccin
This live feed shows all institutional transactions in real time.
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)
SC 13G - DYADIC INTERNATIONAL INC (0001213809) (Subject)